Core Insights - Kyverna Therapeutics, Inc. is a biotechnology company focused on innovative therapies for autoimmune diseases, gaining market attention after Wells Fargo maintained an "Overweight" rating and raised its price target from $31 to $33 [1][6] Stock Performance - The stock has seen a significant increase in options trading activity, with 2,529 call options purchased in a single day, representing a 900% rise from the average daily volume of 253 call options, indicating growing investor interest [2][6] - Kyverna Therapeutics has a market capitalization of approximately $474 million, with a price-to-earnings (P/E) ratio of -2.90, indicating the company is not currently profitable [3] - The stock's beta of 3.65 suggests high volatility compared to the overall market, while the fifty-day moving average is $7.29 and the 200-day moving average is $5.06, showing a strong upward trend [3] Earnings Report - In its latest quarterly earnings report, Kyverna Therapeutics reported an earnings per share (EPS) of -$0.85, beating the consensus estimate of -$0.97 by $0.12, which may have contributed to the stock's recent price increase [4][6] - Analysts expect the company to post an EPS of -3.29 for the current year, indicating ongoing challenges in achieving profitability [4] Price Fluctuations - The stock experienced a 23.12% increase to $10.81, up by $2.03, with trading between $10.40 and $13.67, the latter being its highest price in the past year [5] - The lowest price over the past year was $1.78, highlighting the stock's volatile nature, with a trading volume of 18,535,737 shares [5]